Searchable abstracts of presentations at key conferences in endocrinology

ea0081rc5.4 | Rapid Communications 5: Diabetes, Obesity, Metabolism and Nutrition 2 | ECE2022

Empagliflozin induces endocan expression and alleviates NAFLD through regulation of NF-κB pathway

Nasiri-Ansari Narjes , Kyriakopoulos Georgios , Kyrou Ioannis , Flessa Christina-Maria , Lianou Maria , Karapanagioti Angeliki , Kaltsas Gregory , Papavassiliou Athanasios G , Randeva Harpal S , Kassi Eva

Introduction: Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disorders. Endocan is a novel molecule of endothelial dysfuction which is expressed in liver. SGLT2i have been reported to improve NAFLD through amelioration of inflammation. While there are contradictory results regarding the serum endocan levels in NAFLD patients, data regarding endocan expression in liver tissue are limited. Aim: Herein, we aimed to investigat...